Plasma protease C1-inhibitor treatment is used for the treatment of hereditary angioedema, a rare genetic disorder characterized by recurrent episodes of severe swelling. The treatment helps in inhibiting unregulated activation of the complement system in the body by blocking the activities of C1r and C1s proteases. It provides effective symptomatic and preventive therapy against acute angioedema attacks. The treatment is administered primarily through intravenous injections and is generally well-tolerated with minimal side effects. With no alternative treatment options available currently for acute and prevention of hereditary angioedema attacks, the demand for plasma protease C1-inhibitor concentrates is growing significantly.

The Global plasma protease C1-inhibitor treatment market is estimated to be valued at US$ 6257.99 Bn in 2024 and is expected to exhibit a CAGR of 6.7% over the forecast period 2024 to 2031.

Key Takeaways
Key players operating in the plasma protease C1-inhibitor treatment market are R&D. Koninklijke Philips N.V., Panasonic Corporation, and Procter & Gamble are among the major participants. Koninklijke Pharma is a leading player with its branded drug Cinryze being one of the major treatment options for hereditary angioedema.

The growing incidences of hereditary angioedema globally and limited treatment alternatives are driving the demand for Plasma Protease C1-Inhibitor Treatment Market Size concentrates significantly. As per estimates, about 1 in 10,000 to 1 in 50,000 people suffer from hereditary angioedema worldwide.

Leading manufacturers are focusing on expanding their production facilities and capabilities to cater to the growing demand. Koninklijke Pharma inaugurated a new plasma fractionation facility in the US in 2020 to double its plasma protease C1-inhibitor production capacity.

Get more insights on This Topic- Plasma Protease C1-Inhibitor Treatment Market